Morten Karsdal has been CEO of Nordic Bioscience A/S since June 2010. Since 2002, Morten Karsdal has focused his research on the discovery and development of novel biochemical markers. This has resulted in the development of more than 15 ELISA assays for detecting biomarkers that have been used for research in the fields of fibrosis, osteoporosis and osteoarthritis. One of these assays has been 510(k) approved by the Food and Drug Administration (FDA) in the USA.